- Home
- AMS vs NERV Comparison
AMS vs NERV Comparison
Compare AMS & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMS | NERV |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 269.6M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMS | NERV |
|---|---|---|
| Price | $2.10 | $8.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 6.8K | ★ 139.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 230.00 | 104.12 |
| EPS | ★ N/A | N/A |
| Revenue | $19,714,000.00 | ★ $41,175,600.00 |
| Revenue This Year | $3.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $2.02 | $1.15 |
| 52 Week High | $3.11 | $12.46 |
Technical Indicators
Market Signals| Indicator | AMS | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 68.60 |
| Support Level | $2.04 | $3.69 |
| Resistance Level | $2.19 | $12.46 |
| Average True Range (ATR) | 0.06 | 0.65 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 27.75 | 74.41 |
Price Performance
Historical ComparisonAbout AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.